These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38947311)

  • 1. Corrigendum: Intratumor tertiary lymphatic structure evaluation predicts the prognosis and immunotherapy response of patients with colorectal cancer.
    Feng H; Zhang S; Zhou Q; Han F; Du G; Wang L; Yang X; Zhang X; Yu W; Wei F; Hao X; Ren X; Zhao H
    Front Immunol; 2024; 15():1397764. PubMed ID: 38947311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumor tertiary lymphatic structure evaluation predicts the prognosis and immunotherapy response of patients with colorectal cancer.
    Feng H; Zhang S; Zhou Q; Han F; Du G; Wang L; Yang X; Zhang X; Yu W; Wei F; Hao X; Ren X; Zhao H
    Front Immunol; 2024; 15():1302903. PubMed ID: 38500886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer.
    Sillo TO; Beggs AD; Middleton G; Akingboye A
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LC‑MS/MS metabolome analysis detects the changes in the lipid metabolic profiles of dMMR and pMMR cells.
    Peng W; Tan S; Xu Y; Wang L; Qiu D; Cheng C; Lin Y; Liu C; Li Z; Li Y; Zhao Y; Li Q
    Oncol Rep; 2018 Aug; 40(2):1026-1034. PubMed ID: 29989648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis and immunotherapy efficacy in dMMR&MSS colorectal cancer patients and an MSI status predicting model.
    Fu X; Huang J; Zhu J; Fan X; Wang C; Deng W; Tan X; Chen Z; Cai Y; Lin H; Wang G; Zhang N; Zhu Y; Chen J; Zhan H; Huang S; Fang Y; Li Y; Huang Y
    Int J Cancer; 2024 Aug; 155(4):766-775. PubMed ID: 38594805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Inflammatory Markers of Resectable Colorectal Cancer Patients with Different Mismatch Repair Gene Status.
    Li J; Zhang Y; Xu Q; Wang G; Jiang L; Wei Q; Luo C; Chen L; Ying J
    Cancer Manag Res; 2021; 13():2925-2935. PubMed ID: 33833576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatch Repair Deficient (dMMR) Colorectal Carcinoma in a Pakistani Cohort: Association With Clinical and Pathological Parameters.
    Hashmi AA; Bukhari U; Rizwan R; Faisal F; Kumar R; Malik UA; Zia S; Khan AR; Sham S; Irfan M
    Cureus; 2023 Aug; 15(8):e42781. PubMed ID: 37664303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LDH-A negatively regulates dMMR in colorectal cancer.
    Zhang Y; Li J; Wang B; Chen T; Chen Y; Ma W
    Cancer Sci; 2021 Aug; 112(8):3050-3063. PubMed ID: 34110068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Difference analysis of somatic mutations between deficient mismatch repair and proficient mismatch repair gene related with colorectal cancer].
    Tang XJ; Yang MY; Zhu LZ; Xu D; Yuan Y
    Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1088-1093. PubMed ID: 34695900
    [No Abstract]   [Full Text] [Related]  

  • 10. Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers.
    Hale VL; Jeraldo P; Chen J; Mundy M; Yao J; Priya S; Keeney G; Lyke K; Ridlon J; White BA; French AJ; Thibodeau SN; Diener C; Resendis-Antonio O; Gransee J; Dutta T; Petterson XM; Sung J; Blekhman R; Boardman L; Larson D; Nelson H; Chia N
    Genome Med; 2018 Oct; 10(1):78. PubMed ID: 30376889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers.
    Li J; Guo Y; Liu J; Guo F; Du L; Yang Y; Li X; Ma Y
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
    Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
    Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
    Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
    Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research.
    Wensink E; Bond M; Kucukkose E; May A; Vink G; Koopman M; Kranenburg O; Roodhart J
    Cancer Treat Rev; 2021 Apr; 95():102174. PubMed ID: 33721596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
    Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
    Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intertumoral Heterogeneity of CD3
    Yoon HH; Shi Q; Heying EN; Muranyi A; Bredno J; Ough F; Djalilvand A; Clements J; Bowermaster R; Liu WW; Barnes M; Alberts SR; Shanmugam K; Sinicrope FA
    Clin Cancer Res; 2019 Jan; 25(1):125-133. PubMed ID: 30301825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer.
    Ding K; Mou P; Wang Z; Liu S; Liu J; Lu H; Yu G
    Front Immunol; 2023; 14():1298524. PubMed ID: 38187388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
    Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
    Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial DNA copy number plays opposing roles in T-lymphocyte infiltration of colorectal cancer based on mismatch repair status: new directions for immunotherapy?
    Chen M; Liu H; Liang W; Huang P; Ye F; Cai Y; Liang Z; Xiong L; Kang L; Huang L
    Br J Cancer; 2024 Mar; 130(5):798-807. PubMed ID: 38218920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.